Level I evidence and recommendations from international guidelines have led to prostate magnetic resonance imaging (MRI) becoming integral to the diagnosis and staging of prostate cancer over the past 15 years, with millions of examinations now performed annually around the world. Multiparametric prostate MRI, composed of T2-weighted imaging, diffusion-weighted imaging, and dynamic contrast–enhanced imaging, has changed the standard of care by improving detection of clinically important prostate cancer while decreasing overall biopsy frequency and diminishing detection of clinically insignificant prostate cancer. This has been a remarkable transformation in a relatively brief time frame, particularly considering the typical pace of medical implementation.